Novo Nordisk Says CagriSema Outperforms Semaglutide in Phase 3 Trial

MT Newswires Live02-03 03:11

Novo Nordisk (NVO) said Monday that topline results from a phase 3 trial show CagriSema led to a greater Hemoglobin A1c reduction and weight loss at week 68 compared with semaglutide across all tested doses.

The study, REIMAGINE 2, evaluated the efficacy and safety of CagriSema, which is a combination of cagrilintide and semaglutide, the company said.

The trial included adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor, the company said.

Data show that CagriSema achieved "superior" weight loss of up to 14.2%, according to the company.

The treatment also lowered HbA1c by up to 1.91 percentage points from a baseline of 8.2%, the company said, adding that the trial also confirmed that CagriSema was safe and well-tolerated.

Following the results of REIMAGINE 1 and REDEFINE 3, Novo Nordisk plans to discuss the regulatory pathway for CagriSema in type 2 diabetes with health authorities, the company said.

Price: 59.08, Change: -0.35, Percent Change: -0.59

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608894081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 03:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608894081","market":"us","top_or_hot":-1,"title":"Novo Nordisk Says CagriSema Outperforms Semaglutide in Phase 3 Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Monday that topline results from a phase 3 trial show CagriSema led to a greater Hemoglobin A1c reduction and weight loss at week 68 compared with semaglutide across all tested doses.</p><p>The study, REIMAGINE 2, evaluated the efficacy and safety of CagriSema, which is a combination of cagrilintide and semaglutide, the company said.</p><p>The trial included adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor, the company said.</p><p>Data show that CagriSema achieved \"superior\" weight loss of up to 14.2%, according to the company.</p><p>The treatment also lowered HbA1c by up to 1.91 percentage points from a baseline of 8.2%, the company said, adding that the trial also confirmed that CagriSema was safe and well-tolerated.</p><p>Following the results of REIMAGINE 1 and REDEFINE 3, Novo Nordisk plans to discuss the regulatory pathway for CagriSema in type 2 diabetes with health authorities, the company said.</p><p>Price: 59.08, Change: -0.35, Percent Change: -0.59</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Says CagriSema Outperforms Semaglutide in Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Says CagriSema Outperforms Semaglutide in Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-03 03:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Monday that topline results from a phase 3 trial show CagriSema led to a greater Hemoglobin A1c reduction and weight loss at week 68 compared with semaglutide across all tested doses.</p><p>The study, REIMAGINE 2, evaluated the efficacy and safety of CagriSema, which is a combination of cagrilintide and semaglutide, the company said.</p><p>The trial included adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor, the company said.</p><p>Data show that CagriSema achieved \"superior\" weight loss of up to 14.2%, according to the company.</p><p>The treatment also lowered HbA1c by up to 1.91 percentage points from a baseline of 8.2%, the company said, adding that the trial also confirmed that CagriSema was safe and well-tolerated.</p><p>Following the results of REIMAGINE 1 and REDEFINE 3, Novo Nordisk plans to discuss the regulatory pathway for CagriSema in type 2 diabetes with health authorities, the company said.</p><p>Price: 59.08, Change: -0.35, Percent Change: -0.59</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608894081","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608894081","pubTimestamp":1770059482,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk (NVO) said Monday that topline results from a phase 3 trial show CagriSema led to a greater Hemoglobin A1c reduction and weight loss at week 68 compared with semaglutide across all tested","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK7104":"黄金","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC"},"translate_title":"诺和诺德称CagriSema在3期试验中优于索马鲁肽","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.96},"content_text":"Novo Nordisk (NVO) said Monday that topline results from a phase 3 trial show CagriSema led to a greater Hemoglobin A1c reduction and weight loss at week 68 compared with semaglutide across all tested doses.The study, REIMAGINE 2, evaluated the efficacy and safety of CagriSema, which is a combination of cagrilintide and semaglutide, the company said.The trial included adults with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor, the company said.Data show that CagriSema achieved \"superior\" weight loss of up to 14.2%, according to the company.The treatment also lowered HbA1c by up to 1.91 percentage points from a baseline of 8.2%, the company said, adding that the trial also confirmed that CagriSema was safe and well-tolerated.Following the results of REIMAGINE 1 and REDEFINE 3, Novo Nordisk plans to discuss the regulatory pathway for CagriSema in type 2 diabetes with health authorities, the company said.Price: 59.08, Change: -0.35, Percent Change: -0.59","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608894081","isCrawlerRequest":true}